More annual reports from Nanollose Limited:
2023 ReportPeers and competitors of Nanollose Limited:
Vascular Biogenics Ltd.NANOLLOSE LIMITED
ABN 13 601 676 377
ANNUAL REPORT - 30 JUNE 2022
CONTENTS
CORPORATE DIRECTORY
CHAIRMANS’ LETTER TO SHAREHOLDERS
DIRECTORS’ REPORT
AUDITOR’S INDEPENDENCE DECLARATION
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
STATEMENT OF FINANCIAL POSITION
STATEMENT OF CHANGES IN EQUITY
STATEMENT OF CASH FLOWS
NOTES TO THE FINANCIAL STATEMENTS
DIRECTORS’ DECLARATION
INDEPENDENT AUDITOR’S REPORT
ASX ADDITIONAL INFORMATION
PAGE
3
4
5
24
25
26
27
29
30
52
53
56
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 2
CORPORATE DIRECTORY
DIRECTORS
Wayne Best
Winton Willesee
Terence Walsh
Heidi Beatty
COMPANY SECRETARY
Erlyn Dawson
REGISTERED AND PRINCIPAL OFFICE
AUDITORS
SHARE REGISTRY
HOME EXCHANGE
SOLICITORS
Suite 5 CPC, 145 Stirling Highway
NEDLANDS WA 6009
Telephone: (08) 9389 3120
Website: www.nanollose.com
Email: info@nanollose.com
RSM Australia Partners
Level 32 Exchange Tower, 2 The Esplanade
Perth WA 6000
Automic Registry Services
Level 5, 191 St Georges Terrace
PERTH WA 6000
Telephone: (08) 9324 2099
Australian Securities Exchange
Level 40, Central Park
152-158 St George’s Terrace
PERTH WA 6000
ASX Code: NC6, Options NC6OA
Fairweather Corporate Lawyers
Suite 2, 589 Stirling Highway
Cottesloe WA 6011
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 3
CHAIRMANS’ LETTER TO SHAREHOLDERS NANOLLOSE LIMITED ANNUAL REPORT 2022 PAGE 4 Dear fellow shareholders, It is my pleasure to present to you the 2022 Annual Report for Nanollose Limited (ASX:NC6) (‘Nanollose’ or ‘the Company’), with accompanying financial statements for the year ended 30 June 2022. The period marked a transformational year for Nanollose, underpinned by a series of critical R&D breakthroughs. Excitingly for the board and management team, the successful achievement of those objectives leaves the Company uniquely positioned to pursue commercial opportunities at a time when the global garment sector – one of the world’s largest industries by annual turnover – is shifting its significant resources towards the development of sustainable production solutions. The highlight of the Company’s R&D achievements over the last 12 months was the successful execution of a pilot production spin of Nullarbor™ fibres. The production was undertaken with technology developed jointly by Nanollose and Birla Cellulose and for which a patent application was filed in January 2021. The Tree-Free and Forest-Friendly technology uses various wastes and by-products from the food and agricultural industries. The pilot spin successfully produced over 250kg of Forest-Friendly Nullarbor-20™ fibre with a targeted blend of 20% microbial cellulose and 80% conventional wood pulp. Importantly, what it also demonstrated is that Nanollose’s technology fits seamlessly within existing factory operations of fibre and fabric manufacturers; clear evidence of its practical application and capacity to scale. For the ongoing development of its technology, Nanollose is proud to be working with Birla Cellulose, which is a global leader in sustainable fibre technology research. Birla Cellulose operates as a business unit within the Aditya Birla Group, the world’s largest producer of rayon fibres with over 140,000 employees globally. The collaboration with Birla Cellulose marks one of a number of strategic partnerships established over the past year that help place Nanollose at the forefront of key changes taking place in the global garment industry. Nanollose continued to grow its partner base during the period, securing agreements with several leading clothing and materials manufacturers. This was underpinned by a binding Memorandum of Understanding with multinational clothing company Inditex. The MOU with Inditex, as well as other strategic agreements secured during the period provide considerable validation of the Company’s approach and potential. These partnerships further reflect the ever-increasing level of interest among the world’s largest fashion and textile brands to develop sustainable production solutions. Nanollose’s board and management team are confident it now has the pieces in place to establish a lucrative position at the forefront of the fashion industry's shift towards sustainability. While the year marked a transformational period in R&D, the Company expects the years ahead will bring exciting opportunities to convert its R&D into material commercial contracts. Management has now turned its focus to increasing the scale and percentage of microbial cellulose in its pilot production, and the business development opportunities that this presents. Management is also looking towards securing a long-term commercial supply of microbial cellulose dedicated to fibre production. In addition, now that the fibre technology has transitioned out of the laboratory and into the pilot plant, Nanollose has begun an exciting project to make an animal-free and plastic-free leather alternative from microbial cellulose. As the sustainable fashion shift accelerates, Nanollose aims to be a leading player in the global transition using Australian innovations and world class global partners. I look forward to providing shareholders and investors with more exciting updates as Nanollose executes on its next round of operational targets. Dr Wayne Best Executive Chairman DIRECTORS’ REPORT
The directors present their report, together with the financial statements of Nanollose Limited (referred to hereafter as
the 'Company') for the year ended 30 June 2022.
BOARD OF DIRECTORS
The names and details of the Directors in office during the financial period and until the date of this report are set out
below.
• Wayne Best
Executive Chairman
• Winton Willesee
Non-Executive Director
•
Terence Walsh
Non-Executive Director
• Heidi Beatty
Non-Executive Director
PRINCIPAL ACTIVITIES
Nanollose Limited is a leading biomaterials company, commercialising scalable technology to create fibres and fabrics
with minimal environmental impact. During the financial year, the principal continuing activities of the Company
consisted of research and development, and promotion of the Company’s microbial cellulose technology. The primary
focus has been directed towards the development, scale up and ultimate commercialisation of the Company’s Tree-
Free rayon fibre for use in textiles (NullarborTM) and non-woven applications (Nufolium™).
DIVIDENDS PAID OR RECOMMENDED
There were no dividends declared or paid during the financial year (2021: Nil).
OPERATING RESULTS
During the year, the principal continuing activities of the Company consisted of research and development, and
promotion of the Company’s microbial cellulose technology.
The loss for the Company after providing for income tax amounted to $1,566,504 (30 June 2021: $931,045).
REVIEW OF OPERATIONS
Nanollose Limited (ASX:NC6) is a leading biomaterials company commercialising scalable technology to create forest
friendly fibres and fabrics with minimal environmental impact. Nanollose uses an eco-friendly fermentation process to
grow microbial cellulose and produce tree-free rayon fibres, which are primed to become an alternative to conventional
tree-based rayon fibres.
The Company holds a number of proprietary technologies to convert waste and by-products from the agricultural and
food industries into unique eco-friendly tree-free rayon fibres for textiles, non-woven fabrics and other industrial
applications.
The successful completion of Nanollose’s first pilot scale spin of Nullarbor™ fibres highlighted a period of significant
milestones achieved by the Company in FY22. It was the culmination of a detailed work program undertaken with
strategic partner Birla Cellulose to demonstrate the capacity for the technology to be effectively integrated into existing
factory settings to spin and produce fibre at scale. Successful completion of the pilot spin has resulted in several strategic
collaboration agreements being signed, as well as an MOU with one of the world’s largest fashion retailers.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 5
DIRECTORS’ REPORT
Successful first pilot scale spin of Nullarbor™ fibres:
In February 2022, Nanollose completed its first pilot scale spin of its Nullarbor fibres undertaken with the Company’s
strategic partner, Birla Cellulose. Completion of the first pilot spin process provided valuable technical information and
demonstrated that microbial cellulose can be used to produce Nullarbor-20 lyocell fibre in existing industrial equipment
at scale.
The pilot spin produced over 250kg of Forest-Friendly Nullarbor-20™ fibre and successfully targeted a blend of 20%
microbial cellulose and 80% conventional wood pulp. Future pilot spins will aim to increase the percentage of microbial
cellulose, allowing Nanollose to produce quantities of additional Nullarbor fibres consisting of varied percentages of
Tree-Free microbial cellulose, mixed with other cellulosic materials.
Producing a number of varying blended fibres will provide Nanollose with the opportunity to expand its product range
and appeal to customers at differing price points. This will broaden the Company’s appeal within the lyocell fibre market
which is currently valued at US$1.13 billion, and projected to grow to US$1.71 billion by 20271.
The completion of the first pilot scale fibre production followed months of extensive work, and highlights the capabilities
of Nanollose’s and Birla’s technical teams to overcome the challenges associated with scaling production from
laboratory to industrial grade processing across multiple continents.
Following successful completion of the first pilot spin, the Company has focussed on:
• work required to facilitate completion of a second pilot spin at increased scale;
•
•
preparing yarn and fabric samples from Nullarbor-20 fibre; and
finalising negotiations with strategic partners to trial, test and provide feedback on samples of fibre, yarns and
fabrics to assist in further developing the Company’s product offering.
In order to optimise the value of the fibre from its first pilot spin, Nanollose has sought to allocate samples and provide
limited exclusivity to selected market leaders across key segments of the fashion and textile industries (ie denim,
outdoor, intimates, athleisure, knitwear, sportswear, etc). By doing so, the Company anticipates receiving the most
technically valuable feedback on its product in each market segment, while providing new influential partners with first
and exclusive access to the fibre.
Collaboration agreement with leading denim manufacturer, Orta:
Following its successful pilot spin of Nullarbor-20 lyocell fibre, the Company entered into the first of a number of
collaboration agreements, with sustainable denim manufacturer, Orta Anadolu Ticaret Ve Sanayi İşletmesi T.A.Ş
(“Orta”). Under this agreement, Nanollose and Orta agreed to develop denim materials utilising Nanollose’s Tree-Free
and Forest-Friendly Nullarbor fibres consisting in whole or in part of microbial cellulose.
Orta is a Turkish based company that was established in 1953 as a specialist spinning and weaving company. Since 1985,
the group has been operating as a sustainable denim manufacturer and has a total production of 40 million metres of
denim per annum. Orta supplies denim to a range of luxury brands including Alexander McQueen, Stella McCartnery
and Isabel Marant, as well as leading denim brands such as Levi’s, Lee, Wrangler, Tommy Hilfiger, and Calvin Klein. The
group also provides denim and materials to retail brands, with clients including GAP, Banana Republic and Madewell.
Orta has over 1,500 employees and is a leader in sustainability.
The agreement is in line with the Company’s strategy to grant exclusivity within defined market segments, as Nanollose
and Orta have agreed to work exclusively together in the development of denim fabrics from fibres incorporating
microbial cellulose. Orta has now received an initial 50kg of Nullabor-20 to commence the project, with additional
samples of Nullarbor fibres from subsequent pilot spins to follow as required.
1 https://www.imarcgroup.com/lyocell-fiber-market
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 6
DIRECTORS’ REPORT
Paradise Textiles and Nanollose to develop Nullarbor™ yarns and textiles:
In May 2022, Nanollose entered into a collaboration agreement with Paradise Textiles Limited (“Paradise”), for the
development and manufacture of yarns and textiles incorporating Nanollose’s Tree-Free and Forest-Friendly Nullarbor
fibres. Nanollose has shipped an initial ~135kg of Nullabor-20™ to Paradise, which Paradise will convert into a variety of
yarns and textiles for provision to selected apparel makers and fashion brands with whom Nanollose is currently
finalising agreements.
Paradise is a technology first material science and innovation company, and is the innovation hub of award-winning
apparel manufacturer, Alpine Group. The Alpine Group was founded in 1981 in Taiwan and over the last 40 years has
established global operations including in the US, Singapore, Egypt, Jordan, Dubai, Taiwan and China. Alpine Group is a
trusted partner to some of the biggest brand names in apparel, including: The North Face, Sweaty Betty, American Eagle
Outfitters, Under Armour and Abercrombie and Fitch.
Binding MOU with one of the world’s largest fashion retailers, INDITEX:
In late May 2022, Nanollose entered into a binding memorandum of understanding (‘MOU’) with Industria de Diseño
Textil, S.A. (“INDITEX”), one of the world’s largest fashion retailers. The MOU will see the non-exclusive delivery by
Nanollose to INDITEX of samples of the Company’s Tree-Free (and/or blended) Nullarbor lyocell.
INDITEX is publicly listed on the stock exchanges of Madrid, Barcelona, Bilbao and Valencia, and on the Automated
Quotation System. Their numerous brands include Zara, Pull&Bear, Massimo Dutti, Bershka, Stradivarius, Oysho and
Zara Home, of which they sell into 215 markets through its online platform, and over 6,600 stores in 96 markets.
Nanollose will work with INDITEX, supplying samples of various materials for testing and prototyping, with the view to
Nanollose gaining valuable commercial feedback, whilst INDITEX are allowed early access to the Company’s materials
to determine the potential for use in their various brands.
The MOU with INDITEX is indicative of the significant interest and demand for sustainable solutions in the fashion and
textile industry, and the willingness and commitment of industry leaders to seek out and support the sustainable
innovations that Nanollose has to offer.
Vegan leather opportunity and agreement to develop next generation vegan leather products:
Whilst the Company’s primary focus remains the commercialisation of its fibre technology, the Company has been
undertaking research and development into a microbial cellulose based vegan leather alternative. The vegan leather
market is witnessing strong growth and is expected to be valued at US$89.6Bn by 20252. The rapid rise of the vegan
leather industry is attributed to the increasing awareness of the ethical and environmental concerns over the impact of
traditional leather production among consumers, providing Nanollose with an exceptional opportunity. The vegan
leather project is independent of Nanollose's collaboration with Birla Cellulose, as it does not require the production of
fibre, thereby providing Nanollose with valuable technology and business diversity.
In furtherance of this opportunity, in May 2022, Nanollose entered into a collaboration agreement with innovative
vegan leather and materials company, von Holzhausen, whose vegan leather products replicate the essence of leather
but offer superior performance and a significantly lower carbon impact. von Holzhausen is based in California and has a
factory in the US and Italy that utilises their alternative materials created from plants and recycled fibres. The group has
earned a strong reputation for the sustainability and luxuriousness of their products, which has earned them coverage
across some of the world’s most renowned publications.
Under this agreement, Nanollose will provide von Holzhausen with samples of treated and processed microbial cellulose
in various forms for testing as potential alternatives to leather or other materials either in their initial state or after
further processing by von Holzhausen. As part of the collaboration agreement, each party will work closely together
liaising regularly to exchange information and key specifications to advance the collaboration.
2 https://www.researchandmarkets.com/reports/5005163/vegan-leather-market-global-industry-analysis
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 7
DIRECTORS’ REPORT
The first set of vegan leather samples resulting from the Company’s in-house research have since been delivered to von
Holzhausen for assessment.
Intellectual Property Update:
High Tenacity Lyocell Fibres From Bacterial Cellulose and Method of Preparation Thereof
In January 2022, the Company’s joint patent application (entitled High Tenacity Lyocell Fibres From Bacterial Cellulose
and Method of Preparation Thereof) with Grasim Industries Limited ("Grasim”) was filed globally via the Patent
Cooperation Treaty (PCT). The Company is pleased with the progress being made towards finalising formal patent
protection of its intellectual property and is pleased with the continued commitment from Grasim to the success of the
project.
Plant Growth Media and Method for Making Same – First Granted Patent
In October 2021, Nanollose was granted a patent in China for its Jelli Grow product, “Plant Growth Media and Method
for Making Same”, representing the Company’s first granted patent. The patent was also granted in Japan in May 2022
and is still pending in several other countries. Nanollose’s Jelli Grow™ product is an alternative seed germination and
plant growing material, which is edible, organic, biodegradable and made from the Company’s Tree-Free Microbial
Cellulose. The Company received a high level of customer enquiries for the Jelli Grow product during the period, with
trial samples dispatched to the Middle East and South East Asia, and discussions continuing with additional parties. The
Company’s primary focus remains the commercialisation of its fibre technology.
The Company continues to expand protection for its brand names, including Nullarbor and Nufolium, by pursuing
Trademark registrations and relevant internet domain names.
Lee Mathews designed garment launch at the Copenhagen Global Fashion Summit:
During the year, the Company worked with strategic partner and
leading man-made cellulosic fibre manufacturer, Birla Cellulose, to
produce a small quantity of 100% Tree-Free Nullarbor fibre, for the
purposes of creating the first 100% Nullarbor lyocell garment. The
fibre was spun into yarn using standard industrial yarn making
equipment, and then knitted, using the latest zero-waste 3D
knitting technology, into a concept garment (pictured right)
designed by Australian fashion designer, Lee Mathews.
The garment was successfully
in
collaboration with Birla Cellulose at the Global Fashion Summit in
Copenhagen, the leading international forum for sustainability in
fashion.
in June 2022,
launched
The process demonstrated that Nullarbor lyocell fibre integrates
seamlessly with existing industrial equipment to produce high-
quality garments. Launching at a widely respected global industry
event provided Nanollose with the opportunity to unveil the
garment and promote Nullarbor to a wide audience of industry
professionals.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 8
DIRECTORS’ REPORT
Industrial Transformational Research Hub for Functional and Sustainable Fibres:
Nanollose was part of a consortium of companies and academics which successfully applied for funding from the
Australian Research Council (ARC) to establish an Industrial Transformational Research Hub for Functional and
Sustainable Fibres. The Hub, which will be located at, and administered by, Deakin University, will receive $5m in funding
from the ARC over five years. It will provide the Company with access to world-leading materials science and fibre and
textile expertise, with leveraged research and development funding. Specific research projects for Nanollose are
currently being finalised and expected to begin in the next quarter.
CelluAir Update:
To date, CelluAir in conjunction with researchers at QUT have successfully developed filter material using cellulose
nanofibres with a low pressure drop suitable for use in surgical face masks and respirators. A recent key achievement
from 8 years of research has been the successful testing to AS/NZS 1716:2012 with particle filtration efficiency of 96%
to 99%. Ongoing research into fully bio-degradable filter material is progressing and preliminary testing has been
successful in terms of particle filtration efficiency and breathability.
Nanollose continues to work in close collaboration with CelluAir to develop alternate low-cost sources of cellulose
nanofibres with appropriate properties to achieve both the filtration efficiency and low pressure drop required for good
breathability. Several microbial cellulose samples supplied by Nanollose have been evaluated by CelluAir and refinement
of material is ongoing.
The global market for face masks remains strong with high-volume manufacturers searching for bio-degradable
materials to reduce the impact of environmental pollution from disposal of masks. The market opportunity for filter
media constructed from cellulose nanofibres remains positive and CelluAir is actively engaging with manufacturers in
providing filter samples on the path to commercialisation.
IMPACT OF COVID-19 GLOBAL PANDEMIC
The impact of the Coronavirus (COVID-19) pandemic is ongoing and whilst it has had no direct material financial impact
for the Company up to 30 June 2022, it is not practicable to estimate the potential impact, positive or negative, after
the reporting date.
Various governments (including the Australian government) have imposed restrictions (including quarantines) on the
movement of people and goods as a measure to seek to slow and contain the spread of the Covid-19 virus.
Throughout temporary lockdowns to control the spread of COVID-19, the Company’s operations in Western Australia
have continued unaffected. The Company's key commercialisation focus is on progressing its collaboration with Grasim
Industries and its Birla Cellulose business unit in India. To date, the Company has been able to advance this collaboration
by exchanging materials and technical information including undertaking a first pilot spin at Birla Cellulose’s facilities in
India. However, the spread of the Covid-19 virus in India could delay the movement of goods and people and the ability
of Grasim Industries to meet expected timelines.
The Company's two current supply chain alternatives for purchase of microbial cellulose are located in Indonesia and
China. Again, the spread of the Covid-19 virus and any consequent restriction on the movement of goods and people,
may delay the development of the Company's technologies.
The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other
countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus
that may be provided.
While the pandemic has seen paradigm shifts in many industries, it is encouraging to see that it has only strengthened
the fashion industry’s commitment to sustainability, with Nanollose’s Tree-Free fibres ideally placed to assist the
industry in meeting that commitment.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 9
DIRECTORS’ REPORT
SIGNIFICANT CHANGES IN STATE OF AFFAIRS
Other than detailed in the review of operations, there were no other significant changes in the state of affairs of the
Company during the financial year.
MATTERS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR
No matter or circumstance has arisen since 30 June 2022 that has significantly affected, or may significantly affect the
Company's operations, the results of those operations, or the Company's state of affairs in future financial years.
OUTLOOK
The Company has made significant progress over the past year as it positions itself at the forefront of commercially
viable, eco-friendly fibre alternatives for the fashion and textile industries.
The Company continues to actively work with collaboration partners towards development of denim, yarns and other
textiles using the Company’s Nullarbor fibres, and further refinement of the Company’s fibre products to facilitate
potential commercial supply
These collaboration agreements provide multiple reference points and catalysts for further uptake from global fashion
brands – ongoing discussions are being held with additional potential partners.
Work is ongoing towards the second pilot spin with Birla Cellulose at increased scale, which will provide further valuable
technical information and additional material for projects with existing collaborators and new partners. The Company
is also continuing to progress in-house research initiatives, including microbial cellulose based alternatives to leather in
collaboration with von Holzhausen.
AGM
The Company anticipates that it will hold its next Annual General Meeting (‘AGM’) on or before 25 November 2022. In
accordance with ASX Listing Rule 3.13.1, the closing date for the receipt of nominations from persons wishing to be
considered for election as a director of the Company is 7 October 2022 (35 business days prior to the date of the AGM).
Any nominations must be received in writing no later than 5.00pm (WST) on 7 October 2022, at the Company’s
registered office.
ENVIRONMENTAL REGULATION
The Company is not subject to any significant environmental regulation under Australian Commonwealth or State law.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 10
DIRECTORS’ REPORT
BOARD OF DIRECTORS
Wayne Best – Executive Chairman
Experience and
Expertise
Dr Best has 40 years’ experience in organic chemistry both in academia, government and
industry. Wayne obtained his BSc (Hons) and PhD in Organic Chemistry from The University
of Western Australia. He then spent two years at Imperial College in the UK where he
obtained a DIC, followed by a year at the Australian National University in Canberra. He
then took up a position with ICI Australia’s Research Group in Melbourne for four and a half
years which included a secondment to ICI Agrochemicals in the UK. Following ICI, Wayne
returned to Western Australia and spent ten years at the Chemistry Centre (WA) where he
was responsible for the formation and running of the Medicinal & Biological Chemistry
Section which undertook collaborative R&D into drug discovery and contract synthesis for
the drug discovery and pharmaceutical industries. He then founded Epichem Pty Ltd, a
contract research and drug discovery Company, which he managed for 14 years before
moving full-time to Nanollose in 2018. Wayne is a Fellow of the Royal Australian Chemical
Institute and has held appointments as an Adjunct Associate Professor at both Murdoch
University and The University of Western Australia. He is also a Graduate Member of the
Australian Institute of Company Directors and has served as a Director for several listed and
unlisted biotechnology companies.
BSc (Honours), PhD, DIC, FRACI, GAICD
Other Current
Directorships
None
Former Directorships
in last 3 years
None
Special
Responsibilities
Interests in Shares
and Options
Executive Chairman of the Board
8,431,798 ordinary shares
Winton Willesee – Non-Executive Director
Experience and
Expertise
Mr Willesee is an experienced company director and secretary with over 20 years’ experience
in various roles within the Australian capital markets.
Mr Willesee has considerable experience with ASX listed and other companies over a broad
range of industries having been involved with many successful ventures from early stage
through to large capital development projects.
He has a core expertise in strategy, company development, corporate governance, company
public listings, merger and acquisition transactions and corporate finance.
Mr Willesee holds a Master of Commerce, a Post-Graduate Diploma in Business (Economics
and Finance), a Graduate Diploma in Applied Finance and Investment, a Graduate Diploma in
Applied Corporate Governance, a Graduate Diploma in Education and a Bachelor of Business.
He is a Fellow of the Financial Services Institute of Australasia, a Graduate of the Australian
Institute of Company Directors, a Member of CPA Australia and a Fellow of the Governance
Institute of Australia and the Institute of Chartered Secretaries and Administrators/Chartered
Secretary.
BBus, DipEd, PGDipBus, MCom, FFin, CPA, GAICD, FGIS/FCIS
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 11
DIRECTORS’ REPORT
Other Current
Directorships
Former Directorships
in last 3 years
Interests in Shares
and Options
Non-Executive Chairman of New Zealand Coastal Seafoods Limited (ASX:NZS)
Chairman of UUV Aquabotix Ltd (ASX:UUV)
Non-Executive Director of Hygrovest Ltd (ASX: HGV)
Non-Executive Director of Neurotech International Limited (ASX: NTI)
Non-Executive Director of eSense Lab Ltd (delisted from ASX on 10 August 2021)
8,068,504 ordinary shares
500,000 unlisted $0.147 options expiring 7 December 2024
Terence Walsh – Non-Executive Director
Experience and
Expertise
Mr Walsh is a senior commercial lawyer and manager with more than 20 years of experience
in project development, mining and general commercial law. He initially worked with leading
law firms in Perth and Sydney before moving in house, where he has worked as the General
Counsel of Hancock Prospecting Pty Ltd and prior to that as a Corporate Counsel with Rio Tinto
Ltd. In these roles he has been involved with the legal and commercial aspects associated with
the development and operation of technology and mining projects.
Other Current
Directorships
None
Former Directorships
in last 3 years
Interests in Shares
and Options
Non-Executive Director of Structural Monitoring Systems PLC (ASX:SMN)
965,672 ordinary shares
500,000 unlisted $0.147 options expiring 7 December 2024
Heidi Beatty – Non-Executive Director
Experience and
Expertise
Heidi Beatty, founder of Crown Abbey Ltd is a scientist and innovator who has 20 years’
experience developing consumer and health care products. After gaining a BSc in Chemistry
from the University of York UK, Heidi worked with Johnson & Johnson for 10 years in Europe
and the US. In 2015 Heidi founded Crown Abbey Ltd, a consultancy company that supports
clients in their project launches, combining Project Management and Product Development
across Consumer and Healthcare categories
Other Current
Directorships
None
Former Directorships
in last 3 years
None
Interests in Shares
and Options
68,504 ordinary shares
500,000 unlisted $0.08 options expiring 31 October 2023
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 12
DIRECTORS’ REPORT
COMPANY SECRETARY
Erlyn Dawson – Company Secretary
Experience and
Expertise
Mrs Dawson is an experienced corporate professional with a broad range of corporate
governance and capital markets experience, having been involved with several public
company listings, merger and acquisition transactions and capital raisings for ASX-listed
companies across a diverse range of industries.
Mrs Dawson began her career in corporate recovery and restructuring at Ferrier Hodgson
and is now the Managing Director of corporate services firm, Azalea Consulting, which
provides outsourced company secretarial, accounting and administration services to a
portfolio of ASX-listed companies.
Mrs Dawson holds a Bachelor of Commerce (Accounting and Finance) and a Graduate
Diploma in Applied Corporate Governance. She is a member of the Governance Institute of
Australia/Chartered Secretary.
DIRECTORS’ MEETINGS
Attendances by each Director during the year were as follows:
Director
Wayne Best
Winton Willesee
Terence Walsh
Heidi Beatty
Number
Eligible to
Attend
Number
Attended
5
5
5
5
5
5
5
5
Eligible: represents the number of meetings held during the time the director held office.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 13
DIRECTORS’ REPORT
REMUNERATION REPORT (AUDITED)
The remuneration report details the key management personnel remuneration arrangements for the Company, in
accordance with the requirements of the Corporations Act 2001 and its Regulations.
Key management personnel are those persons having authority and responsibility for planning, directing and controlling
the activities of the Company, directly or indirectly, including all directors.
The remuneration report is set out under the following main headings:
●
●
●
●
●
Principles used to determine the nature and amount of remuneration
Details of remuneration
Service agreements
Share-based compensation
Additional disclosures relating to key management personnel
Principles used to determine the nature and amount of remuneration
The objective of the Company’s executive reward framework is to ensure reward for performance is competitive and
appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic
objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for
the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key
criteria for good reward governance practices:
●
●
●
●
competitiveness and reasonableness
acceptability to shareholders
performance linkage / alignment of executive compensation
transparency
The Board, fulfilling the role of the Nomination and Remuneration Committee, is responsible for determining and
reviewing remuneration arrangements for its directors and executives. The performance of the Company depends on
the quality of its directors and executives. The remuneration philosophy is to attract, motivate and retain high
performance and high-quality personnel.
The Board has structured an executive remuneration framework that is market competitive and complementary to the
reward strategy of the Company.
The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that
it should seek to enhance shareholders' interests by:
●
●
having value creation and capital growth in advance of economic profit as a core component of plan design;
focusing on sustained growth in shareholder wealth, consisting of growth in share price and eventually
dividends, and delivering constant or increasing return on assets as well as focusing the executive on key non-
financial drivers of value; and
●
attracting and retaining high calibre executives.
Additionally, the reward framework should seek to enhance executives' interests by:
●
●
●
rewarding capability and experience;
reflecting competitive reward for contribution to growth in shareholder wealth; and
providing a clear structure for earning rewards.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 14
DIRECTORS’ REPORT
In accordance with best practice corporate governance, the structure of non-executive director and executive director
remuneration is separate.
Non-executive directors’ remuneration
Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive
directors' fees and payments are reviewed from time to time by the Board fulfilling its role as the Nomination and
Remuneration Committee. The Board may, from time to time, receive advice from independent remuneration
consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market. The
chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles
in the external market. The chairman is not entitled to vote on the determination of his own remuneration. Given the
nature of the Company and the more hands-on role the non-executive directors’ play in the operations of the Company
non-executive directors may receive share options or other incentives.
ASX listing rules require the aggregate non-executive directors' remuneration be determined periodically by a general
meeting. The most recent determination was via a resolution of all shareholders on 5 June 2016, where the shareholders
approved a maximum annual aggregate remuneration of $500,000.
Executive directors’ remuneration
The Company aims to reward executives based on their position and responsibility, with a level and mix of remuneration
which has both fixed and variable components.
The executive remuneration and reward framework has four components:
●
●
●
●
base pay and non-monetary benefits
short-term performance incentives
share-based payments
other remuneration such as superannuation and long service leave
The combination of these comprises the executive's total remuneration.
Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed regularly by
the Board fulfilling the role of Nomination and Remuneration Committee based on the overall performance of the
Company and comparable market remunerations.
Executives may receive their fixed remuneration in the form of cash or other benefits where it does not create any
additional costs to the Company and provides additional value to the executive.
The short-term incentives ('STI') program has yet to be finalised. Once adopted it will be designed to align the targets of
Company with the performance hurdles of executives. STI payments will be granted to executives based on specific
annual targets and key performance indicators ('KPI's') being achieved.
The long-term incentives ('LTI') include equity-based payments. Equity securities are awarded to executives with vesting
conditions and expiry dates aligned to the Company’s business plans and targets. The details of the current vesting
conditions and targets are as follows and further detailed in the section on service agreements found below.
There are currently no outstanding unissued Options or Performance Rights.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 15
DIRECTORS’ REPORT
Options
The are no unvested options currently on issue as at the date of this report.
Performance Rights
The are no unvested performance rights currently on issue as at the date of this report.
On 4 December 2020 following shareholder approval, the Company issued 2,000,000 Class D Performance Rights to Dr
Wayne Best. The Class D Performance Rights were to vest on the achievement of either of the following milestones on
or before 31 December 2021:
(i)
Commercial Exploitation:
A.
the Company enters into a commercial agreement or multiple agreements to exploit the Company's
intellectual property via the licensing of the Company's intellectual properties and/or sales of products
made from or related to the Company's microbial cellulose business; and
B.
the Company receives $1,000,000 of gross revenue under that agreement or those agreements; or
(ii)
A ‘Takeover Event’ occurs.
The 2,000,000 Class D Performance Rights issued to Dr Wayne Best expired unvested on 31 December 2021.
Company performance and link to remuneration
Remuneration for certain individuals is directly linked to the performance of the Company. Each key management
personnel held equity securities designed to incentivise them to drive the Company’s performance in line with its
business plans.
A portion of any cash bonus that may be paid to executives will be directly linked to the achievement of goals designed
to align with the Company’s performance.
Details of remuneration
Details of the remuneration of key management personnel of the Company during the year ended 30 June 2022 are set
out in the following tables.
The key management personnel of the Company consisted of the following directors of Nanollose Limited:
Directors
Wayne Best
Executive Chairman
Winton Willesee
Non-Executive Director
Terence Walsh
Heidi Beatty
Non-Executive Director
Non-Executive Director
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 16
DIRECTORS’ REPORT
Key Management Personnel Compensation
The compensation of the Company’s Key Management Personnel is disclosed below:
Cash Salary
and fees
Super-
annuation
Annual
Leave
Options
issued
Equity-
settled
Shares
Equity-
settled
Performance
rights
Total
Fixed
Incentive
($)
($)
($)
($)
($)
($)
($)
(%)
(%)
2022 Key
Management
Person
DIRECTORS
Executives:
Wayne Best
225,000
22,669
18,213
-
Non-executives:
Winton Willesee
35,000
-
-
42,600
Terence Walsh
35,000
-
-
42,600
Heidi Beatty
35,000
-
-
-
TOTAL
330,000
22,669
18,213
85,200
-
-
-
-
-
(65,835)
200,047
100%
-
-
-
-
77,600
77,600
35,000
(65,835)
390,247
45%
45%
100%
55%
55%
-
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 17
DIRECTORS’ REPORT
Cash Salary
and fees
Super-
annuation
Annual
Leave
Options
issued
Equity-
settled
Shares
Equity-
settled
Performance
rights
Total
Fixed
Incentive
($)
($)
($)
($)
($)
($)
($)
(%)
(%)
2021 Key
Management
Person
DIRECTORS
Executives:
Wayne Best
160,000
15,506
24,788
Alfie Germano¹
99,720
8,501
Non-executives:
Winton Willesee
32,667
Terence Walsh
Heidi Beatty
32,667
32,677
-
-
-
-
-
-
-
TOTAL
357,721
24,007
24,788
-
-
-
-
16,571
16,571
5,000
5,000
2,333
2,333
2,333
65,835
271,129
-
-
-
-
113,221
35,000
35,000
51,571
16,999
65,835
505,921
76%
100%
100%
100%
63%
24%
-
-
-
-
37%
¹ Resigned on 15 January 2021
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 18
DIRECTORS’ REPORT
Service Agreements
Remuneration and other terms of employment for key management personnel are formalised in service agreements.
Details of these agreements are as follows:
Name:
Title:
Agreement commenced:
Term of agreement:
Details:
Wayne Best
Executive Chairman
10 April 2018
No fixed term
The remuneration of Dr Wayne Best is $225,000 per year plus statutory
superannuation. Of the $165,000 cash component, Dr Best agreed to forego $5,000
in cash for the 4 months from 1 July 2020 to 31 October 2020 in consideration of the
issue of Shares. From 1 July 2021 cash remuneration reverted to $225,000 per
annum.
Key management personnel have no entitlement to termination payments in the event of removal for misconduct.
Share-based compensation
On 26 November 2021, Shareholders agreed to issue the following options to Directors:
Issue of 500,000 Class J options (NC6OPT 6 $0.147 expiry 07/12/2024) to Winton Willesee valued at $42,600.
Issue of 500,000 Class J options (NC6OPT 6 $0.147 expiry 07/12/2024) to Terence Walsh valued at $42,600.
The options were valued using the Hoadley ESO2 Valuation model using the following assumptions:
Strike price:
Stock price:
Expiry date:
Risk free rate:
Volatility:
Dividend yield: nil
$0.0147
$0.099
7 December 2024
0.98%
134%
Additional information
The loss of the Company for the five years to 30 June 2022 are summarised below:
Sales revenue
EBITDA
EBIT
Loss after income tax
2022 ($)
-
(1,505,105)
(1,570,109)
(1,566,504)
2021 ($)
-
(875,938)
(932,885)
(931,045)
2020 ($)
-
(1,187,793)
(1,241,318)
(1,235,489)
2019 ($)
-
(2,022,299)
(2,054,457)
(2,003,995)
2018 ($)
-
(1,776,703)
(1,783,135)
(1,730,214)
The factors that are considered to affect total shareholders return ('TSR') are summarised below.
Share price at financial year end ($)
Total dividends declared (cents per share)
Basic loss per share (cents per share)
2022
0.071
-
1.05
2021
2020
2019
2018
0.09
-
0.77
0.04
-
1.57
0.05
-
2.67
0.13
-
2.57
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 19
DIRECTORS’ REPORT
Additional disclosures relating to key management personnel
Shareholdings
The number of shares in the Company held during the financial year by each director and other members of key
management personnel of the Company, including their personally related parties, is set out below:
Balance at
the start of
the year
Received
as part of
remuneration
Additions
Disposal on
resignation
Balance at
the end of
the year
8,431,798
8,068,504
768,504
68,504
17,337,310
-
-
-
-
-
-
-
197,168
-
197,168
-
-
-
-
-
8,431,798
8,068,504
965,672
68,504
17,534,478
Ordinary shares
Wayne Best
Winton Willesee
Terence Walsh
Heidi Beatty
Total
Option holdings
The number of options over ordinary shares in the Company held during the financial year by each director and other
members of key management personnel of the Company, including their personally related parties, is set out below:
Balance at
the start of
the year
Issued
Exercised
Expired/
disposal on
resignation
Balance at
the end of
the year
Options over ordinary shares
Wayne Best
Winton Willesee
Terence Walsh
Heidi Beatty
-
-
-
500,000
-
500,000
500,000
-
Total
500,000
1,000,000
-
-
-
-
-
-
-
-
-
-
-
500,000
500,000
500,000
1,500,000
Performance Rights holdings
The number of performance rights in the Company held during the financial year by each director and other members
of key management personnel of the Company, including their personally related parties, is set out below:
Rights to Ordinary shares
Wayne Best
Total
Balance at
the start of
the year
2,000,000
2,000,000
Issued
Converted
Expired/
forfeited/
other
Balance at
the end of
the year
-
-
-
-
(2,000,000)
(2,000,000)
-
-
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 20
DIRECTORS’ REPORT
Other transactions with key management personnel and their related parties during the financial year
(i) Receivable from and payable to key management personnel and their related parties are as follows:
The following balances are outstanding at the reporting date in relation to transactions with key management personnel
and their related parties:
Payable to Valle Corporate Pty Ltd (director related entity of Winton Willesee)
Payable to Azalea Consulting Pty Ltd (director related entity of Winton Willesee)
(ii) Transactions with key management personnel and their related parties
2022
2,000
5,496
2021
2,000
5,496
Payments to Valle Corporate Pty Ltd (director related entity of Winton Willesee) of $22,000 (2021: $21,800) for
bookkeeping and financial reporting services fees.
Payments to Azalea Consulting Pty Ltd (director related entity of Winton Willesee) of $60,451 (2021: $60,451) for
corporate services fees including company secretarial services, and front and registered office services.
All transactions were made on normal commercial terms and conditions and at market rates.
Voting and comments made at the Company's 2021 Annual General Meeting ('AGM')
At the AGM held on 26 November 2021, the Company received votes representing 23,780,289 shares in favour of the
adoption of the remuneration report put to shareholders for the financial year ended 30 June 2021. This represented
91.04% of the votes cast at the AGM.
This is the end of the Audited Remuneration Report.
.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 21
DIRECTORS’ REPORT
SHARES
As at the date of this report, there are 148,886,368 (2021: 148,686,368) fully paid ordinary shares on issue.
Options on issue
Unissued ordinary shares of Nanollose Limited under option as at the date of this report are as follows:
Date of issue
21 May 2020
4 December 2020
20 April 2021
5 July 2021
15 September 2021
7 December 2021
Total
Class of option
No. of Options
Exercise price
Expiry date
NC6OPT1
Class G
Class H
NC6OA
Class I
Class J
800,000
500,000
1,000,000
22,268,635
1,000,000
1,000,000
26,568,635
$0.10
$0.08
$0.10
$0.15
$0.15
31 May 2023
31 October 2023
20 April 2024
5 July 2024
15 September 2024
$0.147
7 December 2024
No person entitled to exercise the options had or has any right by virtue of the option to participate in any share
issue of the Company or of any other body corporate.
Performance Rights on issue
There are no Performance rights on issue as at the date of this report.
Indemnity and insurance of officers
The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity
as a director or executive, for which they may be held personally liable, except where there is a lack of good
faith.
During the financial year, the Company paid a premium in respect of a contract to insure the directors and
executives of the Company against a liability to the extent permitted by the Corporations Act 2001. The contract
of insurance prohibits disclosure of the nature of the liability and the amount of the premium.
Proceedings on behalf of the Company
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings
on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose
of taking responsibility on behalf of the Company for all or part of those proceedings.
Indemnity and insurance of auditor
The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the
auditor of the Company or any related entity against a liability incurred by the auditor.
During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of
the Company or any related entity.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 22
DIRECTORS’ REPORT NANOLLOSE LIMITED ANNUAL REPORT 2022 PAGE 23 Non-audit services Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in Note 16 to the financial statements. The directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The directors are of the opinion that the services as disclosed in Note 16 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons: • all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and • none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards. Corporate Governance The Company’s 2022 Corporate Governance Statement is contained in the ‘Corporate Governance’ section of the Company’s website at https://nanollose.com/about/corporate-governance/. Auditor RSM Australia Partners continues in office in accordance with Section 327 of the Corporations Act 2001. Auditor’s Independence Declaration The Auditor’s Independence Declaration as required under section 307C of the Corporations Act 2001 for the year ended 30 June 2022 has been received and can be found on page 24. This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001. Signed on behalf of the Board of Directors. Winton Willesee Non-Executive Director Dated at Perth, Western Australia 25 August 2022 Level 32 Exchange Tower, 2 The Esplanade Perth WA 6000
GPO Box R1253 Perth WA 6844
RSM Australia Partners
T +61 (0) 8 9261 9100
F +61 (0) 8 9261 9111
www.rsm.com.au
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the audit of the financial report of Nanollose Limited for the year ended 30 June 2022, I
declare that, to the best of my knowledge and belief, there have been no contraventions of:
(i)
(ii)
the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
any applicable code of professional conduct in relation to the audit.
RSM AUSTRALIA PARTNERS
Perth, WA
Dated: 25 August 2022
ALASDAIR WHYTE
Partner
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
RSM Australia Partners is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the RSM network is an independent
accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2022
Notes
30 June 2022 ($)
30 June 2021 ($)
Revenue
Interest income
R&D incentives
Expenses
Research expenses
6,563
1,840
224,611
322,859
231,174
324,699
(448,164)
(393,433)
Promotion and communication expenses
(253,278)
(202,549)
Consultancy and legal expenses
Employee benefits expense
(67,969)
(104,520)
(646,760)
(452,460)
Depreciation expense
(65,004)
(56,948)
Share-based payments
13
(71,765)
145,735
Share of losses of associates using the equity accounting
method
Other expenses
Interest expense
Foreign exchange losses
(LOSS) BEFORE INCOME TAX
Income tax benefit
(LOSS) AFTER INCOME TAX
(16,356)
(23,445)
(224,897)
(164,290)
(2,958)
(3,834)
(527)
(1,566,504)
(931,045)
4
-
-
(1,566,504)
(931,045)
Other comprehensive income/(loss)
-
-
Total comprehensive (loss) for the year
(1,566,504)
(931,045)
Basic loss per share (cents per share)
Diluted loss per share
24
24
(1.05)
(1.05)
(0.77)
(0.77)
The Statement of Profit or Loss and Other Comprehensive Income are to be read in conjunction with the
accompanying notes.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 25
STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2022
CURRENT ASSETS
Cash and cash equivalents
Trade and other receivables
Prepayments
TOTAL CURRENT ASSETS
NON-CURRENT ASSETS
Right of use asset
Investments in associate
Plant and equipment
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
CURRENT LIABILITIES
Trade and other payables
Provisions
Lease liability
Borrowings
TOTAL CURRENT LIABILITIES
TOTAL LIABILITIES
NET ASSETS
EQUITY
Issued capital
Reserves
Accumulated Losses
TOTAL EQUITY
Notes
30 June 2022 ($)
30 June 2021 ($)
5
6
7
8
9
10
11
12
13
14
1,586,252
3,006,597
20,406
42,011
33,018
57,760
1,648,669
3,097,375
37,471
160,199
63,489
261,159
10,447
176,555
97,265
284,267
1,909,828
3,381,642
88,177
55,239
38,093
-
445,166
24,788
11,405
26,475
181,509
507,834
181,509
1,728,319
507,834
2,873,808
8,975,496
1,054,426
8,955,496
653,411
(8,301,603)
(6,735,099)
1,728,319
2,873,808
The Statement of Financial Position is to be read in conjunction with the accompanying notes.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 26
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2022
Balance as at 1 July 2021
Total comprehensive loss for the year
Transactions with owners in their capacity as owners:
Issue of class NC6OA options
Shares issued on exercise of F Class options
I Class options issued (note 13a)
J Class options issued (note 13a)
D Class performance rights not vested (note 13b)
Issued Capital ($)
Reserves ($)
Accumulated
Losses ($)
Total Equity ($)
8,955,496
653,411
(6,735,099)
2,873,808
-
-
20,000
-
-
-
-
(1,566,504)
(1,566,504)
329,250
-
52,400
85,200
(65,835)
-
-
-
-
-
329,250
20,000
52,400
85,200
(65,835)
Balance as at 30 June 2022
8,975,496
1,054,426
(8,301,603)
1,728,319
The Statement of Changes in Equity is to be read in conjunction with the accompanying notes.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 27
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2021
Balance as at 1 July 2020
Total comprehensive loss for the year
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs
Issue of shares to directors in lieu of fees (note 12)
F Class options issued (note 13a)
G Class options issued (note 13a)
H Class options issued (note 13a)
C Class performance rights issued (note 13b)
D Class performance rights issued (note 13b)
Issued Capital ($)
Reserves ($)
Accumulated
Losses ($)
Total Equity ($)
5,788,186
801,086
(5,804,054)
785,218
-
3,041,810
25,500
-
-
-
-
-
-
-
-
33,960
16,571
64,100
167,859
65,835
(931,045)
(931,045)
-
-
-
-
-
-
-
-
-
3,041,810
25,500
33,960
16,571
64,100
167,859
65,835
-
(396,000)
A Class performance rights converted (note 12 and 13b)
100,000
(100,000)
C Class performance rights not vested (note 13b)
-
(396,000)
Balance as at 30 June 2021
8,955,496
653,411
(6,735,099)
2,873,808
The Statement of Changes in Equity is to be read in conjunction with the accompanying notes.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 28
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED
30 JUNE 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Government grants received – Cashflow Boost
R&D incentive received
Notes
30 June 2022 ($)
30 June 2021 ($)
-
224,611
49,904
322,859
Payments to suppliers and employees
(1,610,522)
(1,305,955)
Interest paid
Interest received
(2,958)
6,563
(3,834)
1,840
NET CASH USED IN OPERATING ACTIVITIES
22
(1,382,306)
(935,186)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments For Plant and Equipment
Investment in associate
(5,352)
(72,153)
-
(200,000)
NET CASH USED IN INVESTING ACTIVITIES
8
(5,352)
(272,153)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issue of shares
Payment of share issue costs
Repayment of lease liability
Repayment of borrowings
Proceeds from borrowings
20,000
-
(26,212)
(26,475)
-
3,633,727
(238,708)
-
(26,424)
6,180
NET CASH (USED IN) / FROM FINANCING ACTIVITIES
(32,687)
3,374,775
Net (decrease) / increase in cash and cash equivalents
(1,420,345)
2,167,436
Cash and cash equivalents at beginning of financial year
3,006,597
839,161
Cash and cash equivalents at end of financial year
5
1,586,252
3,006,597
The Statement of Cash Flows is to be read in conjunction with the accompanying notes.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 29
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES
The primary accounting policies adopted in the preparation of the Financial Statements are set out below. These
policies have been consistently applied to all years presented, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early
adopted.
The following Accounting Standards and Interpretations are most relevant to the Company:
a. Basis of Preparation
These general-purpose financial statements have been prepared in accordance with Australian Accounting
Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the
Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply
with International Financial Reporting Standards as issued by the International Accounting Standards Board
('IASB').
b. Historical cost convention
The financial statements have been prepared under the historical cost convention, except for, where applicable,
certain financial assets and liabilities.
c. Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also
requires management to exercise its judgement in the process of applying the Company’s accounting policies.
The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are
significant to the financial statements, are disclosed in note 2.
Operating segments
Operating segments are presented using the ‘management approach’, where the information presented is on
the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is
responsible for the allocation of resources to operating segments and assessing their performance.
Foreign currency translation
The financial statements are presented in Australian dollars, which is Nanollose Limited’s functional and
presentation currency.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 30
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Foreign currency transactions
Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the
dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions
and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in
foreign currencies are recognised in profit or loss.
Revenue recognition
Interest
Interest income is recognised as interest accrues using the effective interest method. This is a method of
calculating the amortised cost of a financial asset and allocating the interest income over the relevant period
using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through
the expected life of the financial asset to the net carrying amount of the financial asset.
Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.
Income tax
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on
the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities
attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where
applicable.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be
applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or
substantively enacted, except for:
●
●
When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset
or liability in a transaction that is not a business combination and that, at the time of the transaction,
affects neither the accounting nor taxable profits; or
When the taxable temporary difference is associated with interests in subsidiaries, associates or joint
ventures, and the timing of the reversal can be controlled, and it is probable that the temporary
difference will not reverse in the foreseeable future.
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is
probable that future taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date.
Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits
will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are
recognised to the extent that it is probable that there are future taxable profits available to recover the asset.
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax
assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the
same taxable authority on either the same taxable entity or different taxable entities which intend to settle
simultaneously.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 31
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Earnings per share
Basic earnings per share
Basic earnings per share is calculated by dividing the profit attributable to the owners of the Company, excluding
any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares
outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial
year.
Diluted earnings per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into
account the after income tax effect of interest and other financing costs associated with dilutive potential
ordinary shares and the weighted average number of shares assumed to have been issued for no consideration
in relation to dilutive potential ordinary shares.
Current and non-current classification
Assets and liabilities are presented in the statement of financial position based on current and non-current
classification.
An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in
the Company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised
within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being
exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are
classified as non-current.
A liability is classified as current when: it is either expected to be settled in the Company's normal operating
cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting
period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the
reporting period. All other liabilities are classified as non-current.
Cash and cash equivalents
Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-
term, highly liquid investments with original maturities of three months or less that are readily convertible to
known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of
cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown
within borrowings in current liabilities on the statement of financial position.
Trade and other receivables
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the
effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for
settlement within 30 days.
The Company has applied the simplified approach of measuring expected credit losses, which uses a lifetime
expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on
days overdue.
Other receivables are recognised at amortised cost, less any allowance for expected credit losses.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 32
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATAMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Plant and equipment
Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost
includes expenditure that is directly attributable to the acquisition of the items.
Depreciation is calculated on a straight-line or diminishing balance basis to write off the net cost of each class
of plant and equipment over their expected useful lives as follows:
Plant and equipment
Leasehold improvements
3-5 years
4 years
diminishing balance
straight-line
The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each
reporting date.
Leasehold improvements and plant and equipment under lease are depreciated over the unexpired period of
the lease or the estimated useful life of the assets, whichever is shorter.
An item of plant and equipment is derecognised upon disposal or when there is no future economic benefit to
the Company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or
loss. Any revaluation surplus reserve relating to the item disposed of is transferred directly to retained profits.
Right-of-use assets
A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at
cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments
made at or before the commencement date net of any lease incentives received, any initial direct costs incurred,
and, except where included in the cost of inventories, an estimate of costs expected to be incurred for
dismantling and removing the underlying asset, and restoring the site or asset.
Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the
estimated useful life of the asset, whichever is the shorter. Where the Company expects to obtain ownership of
the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets
are subject to impairment or adjusted for any remeasurement of lease liabilities.
The Company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term
leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are
expensed to profit or loss as incurred.
Research and development
Research costs are expensed in the period in which they are incurred. Development costs are capitalised when
it is probable that the project will be a success considering its commercial and technical feasibility; that the
Company is able to use or sell the asset; the Company has sufficient resources and intent to complete the
development; and its costs can be measured reliably. Capitalised development costs are amortised on a straight-
line basis over the period of their expected benefit.
Trade and other payables
These amounts represent liabilities for goods and services provided to the Company prior to the end of the
financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and
are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 33
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Employee benefits
Short-term employee benefits
Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected
to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid
when the liabilities are settled.
Other long-term employee benefits
The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting
date are measured at the present value of expected future payments to be made in respect of services provided
by employees up to the reporting date using the projected unit credit method. Consideration is given to
expected future wage and salary levels, experience of employee departures and periods of service. Expected
future payments are discounted using market yields at the reporting date on corporate bonds with terms to
maturity and currency that match, as closely as possible, the estimated future cash outflows.
Share-based payments
Equity-settled and cash-settled share-based compensation benefits are provided to employees.
Equity-settled transactions are awards of shares, or options over shares that are provided to employees in
exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services,
where the amount of cash is determined by reference to the share price.
The cost of equity-settled transactions is measured at fair value on grant date. Fair value is independently
determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility
of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option,
together with non-vesting conditions that do not determine whether the Company receives the services that
entitle the employees to receive payment. No account is taken of any other vesting conditions.
The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over
the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the
award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting
period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each
reporting date less amounts already recognised in previous periods.
The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying
either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions
on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is
calculated as follows:
•
•
during the vesting period, the liability at each reporting date is the fair value of the award at that date
multiplied by the expired portion of the vesting period.
from the end of the vesting period until settlement of the award, the liability is the full fair value of the
liability at the reporting date.
All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the
cash paid to settle the liability.
Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to
market conditions are considered to vest irrespective of whether or not that market condition has been met,
provided all other conditions are satisfied.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 34
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been
made. An additional expense is recognised, over the remaining vesting period, for any modification that
increases the total fair value of the share-based compensation benefit as at the date of modification.
If the non-vesting condition is within the control of the Company or employee, the failure to satisfy the condition
is treated as a cancellation. If the condition is not within the control of the Company or employee and is not
satisfied during the vesting period, any remaining expense for the award is recognised over the remaining
vesting period, unless the award is forfeited.
If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any
remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled
award, the cancelled and new award is treated as if they were a modification.
Lease liabilities
A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at
the present value of the lease payments to be made over the term of the lease, discounted using the interest
rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing
rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments
that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price
of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated
termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in
the period in which they are incurred.
Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are
remeasured if there is a change in the following: future lease payments arising from a change in an index or a
rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a
lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss
if the carrying amount of the right-of-use asset is fully written down.
Finance costs
Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are
expensed in the period in which they are incurred.
Borrowings
Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction
costs. They are subsequently measured at amortised cost using the effective interest method.
Fair value measurement
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure
purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date; and assumes that the
transaction will take place either: in the principal market; or in the absence of a principal market, in the most
advantageous market.
Fair value is measured using the assumptions that market participants would use when pricing the asset or
liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement
is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for
which sufficient data are available to measure fair value, are used, maximising the use of relevant observable
inputs and minimising the use of unobservable inputs.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 35
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Assets and liabilities measured at fair value are classified into three levels using a fair value hierarchy that reflects
the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting
date and transfers between levels are determined based on a reassessment of the lowest level of input that is
significant to the fair value measurement.
For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise
is either not available or when the valuation is deemed to be significant. External valuers are selected based on
market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from
one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the
latest valuation and a comparison, where applicable, with external sources of data.
Issued capital
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction,
net of tax, from the proceeds.
Dividends
Dividends are recognised when declared during the financial year and no longer at the discretion of the
Company.
Goods and Services Tax ('GST') and other similar taxes
Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is
not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the
asset or as part of the expense.
Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of
GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the
statement of financial position.
Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing
activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.
Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the
tax authority.
Associates
Associates are entities over which the Company has significant influence but not control or joint control.
Investments in associates are accounted for using the equity method. Under the equity method, the share of
the profits or losses of the associate is recognised in profit or loss and the share of the movements in equity is
recognised in other comprehensive income. Investments in associates are carried in the statement of financial
position at cost plus post acquisition changes in the Company’s share of net assets of the associate. Dividends
received or receivable from associates reduce the carrying amount of the investment.
When the Company's share of losses in an associate equals or exceeds its interest in the associate, including any
unsecured long-term receivables, the Company does not recognise further losses, unless it has incurred
obligations or made payments on behalf of the associate.
The Company discontinues the use of the equity method upon the loss of significant influence over the associate
and recognises any retained investment at its fair value. Any difference between the associate's carrying
amount, fair value of the retained investment and proceeds from disposal is recognised in profit or loss.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 36
NOTES TO THE FINANCIAL STATEMENTS
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
New Accounting Standards and Interpretations not yet mandatory or early adopted
Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet
mandatory, have not been early adopted by the Company for the annual reporting period ended 30 June 2022.
The Company has not yet assessed the impact of these new or amended Accounting Standards and
Interpretations.
NOTE 2. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS
The preparation of the financial statements requires management to make judgements, estimates and
assumptions that affect the reported amounts in the financial statements. Management continually evaluates
its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses.
Management bases its judgements, estimates and assumptions on historical experience and on other various
factors, including expectations of future events, management believes to be reasonable under the
circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results.
The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are
discussed below.
Share-based payment transactions
The Company measures the cost of equity-settled transactions with employees by reference to the fair value of
the equity instruments at the date at which they are granted. Management has applied a probability estimate
to the vesting conditions being met, since the Company was unable to reliably measure the fair value of the
services received. The accounting estimates and assumptions relating to equity-settled share-based payments
would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period
but may impact profit or loss and equity.
NOTE 3. OPERATING SEGMENTS
Primary Reporting Format – Business Segments
The Company has one geographical location which is Australia. The Company’s sole operations are research and
development, and promotion of the Company’s nanocellulose technology from that location.
Identification of reportable operating segments
The operating segment identified is based on the internal reports that are reviewed and used by the Directors
(who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in
determining the allocation of resources. There is no aggregation of operating segments. The CODM reviews
EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation). The accounting policies adopted for
internal reporting to the CODM are consistent with those adopted in the financial statements. The information
reported to the CODM is on at least a quarterly basis.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 37
NOTES TO THE FINANCIAL STATEMENTS
NOTE 4. INCOME TAX EXPENSE
Reconciliation of income tax expense and tax at the statutory rate
Loss before income tax expense from continuing operations
(1,566,504)
(931,045)
30 June 2022 ($)
30 June 2021 ($)
Tax benefit at the statutory tax rate of 30% (2021: 30%)
469,951
279,314
Tax effect amounts which are not deductible/(taxable) in
calculating taxable income:
Non-assessable income
Other non-deductible expenses
-
118,800
(22,072)
(95,499)
447,879
302,615
Future tax benefit not recognised
(447,879)
(302,615)
Income tax expense
-
-
Unrecognised deferred tax balances
The Company does not currently recognise any deferred tax asset arising from its tax losses. The Directors
estimate that the potential deferred tax assets at 30% not brought to account attributable to tax losses carried
forward at reporting date is approximately $1,622,968 (2021: $1,175,089).
The losses have not been brought to account because the Directors do not believe it is appropriate to regard
realisation of those deferred tax assets as being probable. The benefit of these deferred tax assets will only be
obtained if:
(1)
(2)
(3)
the Company derives future assessable income of a nature and of an amount sufficient to enable the
benefit from the deductions for the temporary differences to be realised;
the Company continues to comply with the conditions for deductibility imposed by tax legislation; and
no changes in tax legislation adversely affect the Company in realising the benefit from the
deductions for the temporary differences.
NOTE 5. CASH AND CASH EQUIVALENTS
Cash at bank
Term deposit [1]
30 June 2022 ($)
30 June 2021 ($)
366,252
52,856
1,220,000
2,953,741
[1] Term deposit amount includes $20,000 used as security for credit cards.
1,586,252
3,006,597
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 38
NOTES TO THE FINANCIAL STATEMENTS
NOTE 6. RIGHT OF USE ASSET
Right of use asset
Accumulated depreciation
Right of use asset
Opening balance
Additions
Closing balance
Accumulated depreciation
Opening balance
Depreciation expense
30 June 2022 ($)
30 June 2021 ($)
153,190
100,289
(115,719)
(89,842)
37,471
10,447
100,289
52,901
153,190
100,289
-
100,289
(89,842)
(64,770)
(25,877)
(115,719)
37,471
(25,072)
(89,842)
10,447
NOTE 7. INVESTMENT IN ASSOCIATE
Interests in associate are accounted for using the equity method of accounting.
Name
Principal place of business /
CelluAir Pty Ltd
Australia
20
20
Country of incorporation
30 June 2022 (%)
30 June 2021 (%)
Ownership Interest
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 39
NOTES TO THE FINANCIAL STATEMENTS
NOTE 7. INVESTMENT IN ASSOCIATE (CONTINUED)
Summarised financial information
Summarised statement of financial position
Current assets
Non-current assets
Total assets
Current liabilities
Net assets
Summarised statement of profit or loss and other comprehensive
income
Expenses
Loss before income tax
Income tax expense
Loss after income tax
Other comprehensive loss
Total comprehensive loss
Reconciliation of the Company’s carrying amount
Opening carrying amount
Addition
Share of loss after income tax
Closing carrying amount
Commitments
CelluAir Pty Ltd
30 June 2022 ($)
30 June 2021 ($)
83,895
12,269
96,164
(5,959)
90,205
(81,780)
(81,780)
-
122,774
-
122,774
-
122,774
(117,226)
(117,226)
-
(81,780)
(117,226)
-
-
(81,780)
(117,226)
176,555
-
(16,356)
160,199
-
200,000
(23,445)
176,555
CelluAir Pty Ltd has no commitments not recognised as liabilities as at 30 June 2022 (2021: $nil).
Contingent assets
CelluAir Pty Ltd has no contingent assets as at 30 June 2022 (2021: $nil).
Contingent liabilities
CelluAir Pty Ltd has no contingent liabilities as at 30 June 2022 (2021: $nil).
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 40
NOTES TO THE FINANCIAL STATEMENTS
NOTE 8. PLANT AND EQUIPMENT
Plant and equipment – at cost
Accumulated depreciation
Leasehold improvements – at cost
Accumulated depreciation
30 June 2022 ($)
30 June 2021 ($)
142,632
137,281
(92,800)
(58,208)
49,832
79,073
58,251
(44,594)
13,657
63,489
58,251
(40,059)
18,192
97,265
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year
are set out below:
Balance at 30 June 2021
Additions
Depreciation expense
Plant and
equipment ($)
Leasehold
improvements ($)
Total ($)
79,073
18,192
97,265
5,351
(34,592)
-
(4,535)
5,351
(39,127)
Balance at 30 June 2022
49,832
13,657
63,489
NOTE 9. TRADE AND OTHER PAYABLES
Trade payables
Other payables
Refer to Note 23 for further information on financial instruments.
30 June 2022 ($)
30 June 2021 ($)
37,163
51,014
108,106
337,060
88,177
445,166
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 41
NOTES TO THE FINANCIAL STATEMENTS
NOTE 10. PROVISIONS
Provision for annual leave
30 June 2022 ($)
30 June 2021 ($)
55,239
24,788
The current provision for employee benefits includes all unconditional entitlements where employees have
completed the required period of service and also those where employees are entitled to pro-rata payments in
certain circumstances. The entire amount is presented as current since the Company does not have an
unconditional right to defer settlement.
NOTE 11. LEASE LIABILITY
Lease liability - current
30 June 2022 ($)
30 June 2021 ($)
38,093
11,405
The lease liability relates to the lease of premises with an annual rental of $27,600 and an expiry date of 25
November 2023, hence the remaining liability has been classified as current.
NOTE 12. EQUITY - ISSUED CAPITAL
Ordinary shares - fully paid
148,886,368
148,686,368
8,975,496
8,955,496
2022 (shares)
2021(shares)
2022 ($)
2021 ($)
Movements in ordinary share capital
Balance as at 30 June 2021
148,686,368
8,955,496
Date
Shares
Issue price
$
Conversion of options
16 November 2021
200,000
$0.100
20,000
Balance as at 30 June 2022
148,886,368
8,975,496
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 42
NOTES TO THE FINANCIAL STATEMENTS
NOTE 12. EQUITY - ISSUED CAPITAL (CONTINUED)
Balance as at 30 June 2020
105,749,991
5,788,186
Date
Shares
Issue price
$
Issue of shares to sophisticated investors
6 October 2020
12,000,000
$0.055
660,000
Issue of shares to directors in lieu of fees
4 December 2020
499,104
$0.051
25,500
Conversion of Performance Rights
4 December 2020
Issue of shares - lieu of cash fees for advisors
15 January 2021
Conversion of options
25 January 2021
500,000
200,000
200,000
$0.200
$0.050
$0.100
100,000
10,000
20,000
Issue of shares to sophisticated investors
23 April 2021
28,537,273
$0.100
2,853,727
Issue of shares to sophisticated investors
24 June 2021
1,000,000
$0.100
100,000
Transaction costs relating to share issues
Balance as at 30 June 2021
148,686,368
(601,917)
8,955,496
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the
Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares
have no par value and the Company does not have a limited amount of authorised capital.
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a
poll each share shall have one vote.
NOTE 13. EQUITY – RESERVES
Options reserve (a)
Performance rights reserve (b)
30 June 2022 ($)
30 June 2021 ($)
1,054,426
587,576
-
1,054,426
65,835
653,411
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 43
NOTES TO THE FINANCIAL STATEMENTS
NOTE 13. EQUITY – RESERVES (CONTINUED)
(a) Movements in options reserve
Balance as at 30 June 2020
No. of Options
45,733,332
$
472,945
30 September 2020 lapsed 1,100,000 Class C
(1,100,000)
-
4 December 2020 issue of 2,400,000 Class F
2,400,000
33,960
4 December 2020 issue of 500,000 Class G
500,000
16,571
31 December 2020 lapsed 23,783,333 Class A
(23,783,333)
-
31 December 2020 lapsed 18,749,999 NC6OPT
(18,749,999)
-
15 January 2021 lapsed 1,100,000 Class D
(1,100,000)
-
25 January 2021 exercised 200,000 NC6OPT1
(200,000)
-
20 April 2021 issue 1,000,000 Class H
1,000,000
64,100
Balance as at 30 June 2021
4,700,000
587,576
5 July 2021 issue of NC6OA options to placement participants
& lead manager
22,268,635
329,250
15 September 2021 issue of I Class options to employee
1,000,000
52,400
16 November 2021 exercise of F Class options
(200,000)
-
30 November 2021 expiry of F Class options
(2,200,000)
-
7 December 2021 issue of J Class options to Directors
1,000,000
85,200
Balance as at 30 June 2022
26,568,635
1,054,426
For the options granted during the current financial year, the valuation model inputs used to determine the
fair value at the grant date, are as follows:
The expense of $85,200 for options issued to Directors was calculated using the Hoadley ESO2 valuation model
using the following inputs:
Number of options in series
Grant date
Expiry date
Share price at grant date
Exercise price
Expected volatility
Dividend yield
Risk-free interest rate
Fair value at grant date
Unlisted options
NC6OPT 6
1,000,000
26 Nov 2021
7 Dec 2024
$0.099
$0.1470
134%
nil
0.98%
$0.0852
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 44
NOTES TO THE FINANCIAL STATEMENTS
NOTE 13. EQUITY – RESERVES (CONTINUED)
The expense of $52,400 for options issued to employees was calculated using the Hoadley ESO2 valuation model
using the following inputs:
Number of options in series
Grant date
Expiry date
Share price at grant date
Exercise price
Expected volatility
Dividend yield
Risk-free interest rate
Fair value at grant date
Unlisted options
NC6OPT 5
1,000,000
14 Sept 2021
15 Sept 2024
$0.099
$0.15
133%
nil
0.14%
$0.0524
The options on issue as at 30 June 2022 are as follows:
Grant date
Class of option
No. of Options
Exercise price
Expiry date
21 May 2020
NC6OPT1
800,000
$0.10
31 May 2023
4 December 2020
20 April 2021
5 July 2021
14 September 2021
26 November 2021
Total
Class G
Class H
NC6OA
Class I
Class J
500,000
$0.08
31 October 2023
1,000,000
$0.10
20 April 2024
22,268,635
1,000,000
1,000,000
26,568,635
$0.15
$0.15
5 July 2024
15 September 2024
$0.147
7 December 2024
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 45
NOTES TO THE FINANCIAL STATEMENTS
NOTE 13. EQUITY – RESERVES (CONTINUED)
(b) Movements in performance rights reserve
Balance as at 30 June 2020
Conversion of A Class Performance Rights
C Class Performance rights issued in prior year - expense recognised for the year end 30 June
2021
D Class Performance rights issued to director - expense recognised for the year end 30 June
2021
C Class Performance rights lapsed
Balance as at 30 June 2021
No. of
Performance
Rights
$
4,500,000
328,141
(500,000)
(100,000)
-
167,859
2,000,000
65,835
(4,000,000)
(396,000)
2,000,000
65,835
D Class Performance rights lapsed
(2,000,000)
(65,835)
Balance as at 30 June 2022
-
-
There are no Performance Rights on issue as at 30 June 2022.
(c) A summary of share-based payments recognised as expenses/share issued costs for the year are as
follows:
Share-based payment – employees/KMP
30 June 2022 ($)
30 June 2021 ($)
Options issued to employee
Options issued to directors
Performance rights issued to directors
Performance rights to director lapsed
Share-based payment – supplier/consultant
Options issued to lead manager
Options issued to consultant
52,400
85,200
-
(65,835)
71,765
329,250
-
329,250
-
16,571
233,694
(396,000)
(145,735)
33,960
64,100
98,060
NOTE 14. EQUITY – ACCUMULATED LOSSES
Accumulated losses at the beginning of the financial year
Loss after income tax expense for the year
30 June 2022 ($)
30 June 2021 ($)
(6,735,099)
(1,566,504)
(5,804,054)
(931,045)
Accumulated losses at the end of the financial year
(8,301,603)
(6,735,099)
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 46
NOTES TO THE FINANCIAL STATEMENTS
NOTE 15. KEY MANAGEMENT PERSONNEL COMPENSATION
Key management personnel remuneration has been included in the Remuneration Report section of the
Directors’ Report.
Short-term employee benefits
Post-employment benefits
Annual leave payments
Share-based payments - shares
Share-based payments - options
Share-based payments - performance rights
30 June 2022 ($)
30 June 2021 ($)
330,000
22,669
18,213
-
85,200
(65,835)
390,247
357,721
24,007
24,788
16,999
16,571
65,835
505,921
NOTE 16. REMUNERATION OF AUDITORS
During the financial year the following fees were paid or payable for services provided by RSM Australia
Partners, the auditor of the Company:
Audit services – RSM Australia Partners
Auditor review of the financial statements
Other services – RSM Australia Partners
Preparation of income tax return
30 June 2022 ($)
30 June 2021 ($)
33,500
30,750
6,500
40,000
5,500
36,250
NOTE 17. COMMITMENTS
The Company has no commitments not recognised as liabilities as at 30 June 2022 (2021: $nil).
NOTE 18. CONTINGENT ASSETS
The Company has no contingent assets as at 30 June 2022 (2021: $nil).
NOTE 19. CONTINGENT LIABILITIES
The Company has no contingent liabilities as at 30 June 2022 (2021: $nil).
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 47
NOTES TO THE FINANCIAL STATEMENTS
NOTE 20. EVENTS AFTER THE REPORTING PERIOD
No matter or circumstance has arisen since 30 June 2022 that has significantly affected, or may significantly
affect the Company's operations, the results of those operations, or the Company's state of affairs in future
financial years.
NOTE 21. RELATED PARTY TRANSACTIONS
Disclosures relating to key management personnel are set out in Note 15 and the Remuneration Report included
in the Directors’ Report.
Transactions with key management personnel and their related parties
Payments to Valle Corporate Pty Ltd (director related entity of Winton Willesee) of $22,000 (2021: $21,800) for
bookkeeping and financial reporting services fees.
Payments to Azalea Consulting Pty Ltd (director related entity of Winton Willesee) of $60,451 (2021: $60,451)
for corporate services fees including company secretarial services, and front and registered office services.
Receivable from and payable to key management personnel and their related parties are as follows:
The following balances are outstanding at the reporting date in relation to transactions with key management
personnel and their related parties:
Payable to Valle Corporate Pty Ltd (director related entity of Winton Willesee)
Payable to Azalea Consulting Pty Ltd (director related entity of Winton Willesee)
2022
2,000
5,496
2021
2,000
5,496
Transactions between related parties are on normal commercial terms and conditions no more favourable than
those available to other parties unless otherwise stated.
There were no further transactions with Directors or other Key Management Personnel, including their
personally related parties, not disclosed in Note 15 or the above.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 48
NOTES TO THE FINANCIAL STATEMENTS
NOTE 22. RECONCILIATION OF LOSS AFTER INCOME TAX TO NET CASH USED IN OPERATING ACTIVITIES
Loss after income tax expense for the year
Adjustments for:
Depreciation of plant and equipment
Depreciation of right-of-use-asset
Equity accounted expense
Share based payments
Expenses paid via equity instruments
Change in operating assets and liabilities:
Trade and other receivables
Prepayments
Provisions
Trade and other payables
Net cash used in operating activities
30 June 2022 ($) 30 June 2021 ($)
(1,566,504)
(931,045)
39,128
25,876
16,356
71,765
31,876
25,072
23,445
(145,735)
-
64,100
12,612
15,749
30,451
(27,739)
34,353
(34,830)
(6,679)
4,257
(1,382,306)
(935,186)
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 49
NOTES TO THE FINANCIAL STATEMENTS
NOTE 23. FINANCIAL INSTRUMENTS
The Company’s activities are being funded by equity and are not exposed to significant financial risks. There
are no speculative or financial derivative instruments. The Company holds the following financial instruments:
Financial assets
Cash and cash equivalents
Trade and other receivables
Financial liabilities
Trade and other payables
Lease liability (current and non-current)
Borrowings
30 June 2022 ($)
30 June 2021 ($)
1,586,252
3,006,597
20,406
33,018
1,606,658
3,039,615
88,177
445,166
38,093
11,405
-
26,475
126,270
483,046
The Company’s principal financial instruments comprise of cash. The main purpose of these financial
instruments is to fund the Company’s operations.
It is, and has been throughout the period under review, the Company’s policy that no trading in financial
instruments shall be undertaken. The main risks arising from the Company’s financial operations are credit risk,
capital risk and liquidity risk. The Directors’ review and agree policies for managing each of these risks and they
are summarised below:
(a)
Credit risk
Management does not actively manage credit risk as the Company has no significant exposure to credit risk from
external parties at year end as there are no trade receivables.
(b)
Capital risk
The Company’s objectives when managing capital are to safeguard its ability to continue as a going concern, so
that it can continue to provide returns for shareholders and benefits for other stakeholders and to maintain an
optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the
Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new
shares or sell assets to reduce debt.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 50
NOTES TO THE FINANCIAL STATEMENTS
NOTE 23. FINANCIAL INSTRUMENTS (CONTINUED)
(c)
Liquidity risk
Maturity profile of financial instruments
Prudent liquidity risk management implies maintaining sufficient cash balances and access to equity funding.
The Company’s exposure to the risk of changes in market interest rates relates primarily to cash assets and
floating interest rates. The Company does not have significant interest-bearing assets and is not materially
exposed to changes in market interest rates.
The Company does not have financial instruments with maturity exceeding 12 months (2021: $nil).
Sensitivity analysis – interest rates
The sensitivity effect of possible interest rate movements has not been disclosed as they are not material.
(d)
Net fair value of financial assets and liabilities
Unless otherwise stated, the carrying amount of financial instruments reflect their fair value.
NOTE 24. LOSS PER SHARE
Basic loss per share (cents)
Diluted loss per share (cents)
30 June 2022 ($)
30 June 2021 ($)
1.05
1.05
0.77
0.77
30 June 2022 ($)
30 June 2021 ($)
Net loss used in the calculation of basic and diluted loss per share
Weighted average number of ordinary shares outstanding during the year
used in the calculation of basic loss per share
Weighted average number of ordinary shares outstanding during the year
used in the calculation of diluted loss per share
(1,566,504)
(931,045)
148,810,204
120,612,310
148,810,204
120,612,310
As the Company is in a loss position, the diluted loss per share calculation excludes the dilutive effect of the
performance rights and options issued and not yet converted to ordinary shares.
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 51
DIRECTOR’S DECLARATION NANOLLOSE LIMITED ANNUAL REPORT 2022 PAGE 52 In the opinion of the Directors of Nanollose Limited: (a) the Financial Statements, comprising the statement of profit or loss and other comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity, and Notes set out on pages 25 to 51, are in accordance with the Corporations Act 2001, including: (i) giving a true and fair view of the Company’s financial position as at 30 June 2022 and of their performance, for the financial period ended on that date; and (ii) complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and Corporations Regulations 2001; and other mandatory professional reporting requirements. (b) the Financial Report also complies with International Financial Reporting Standards as disclosed in Note 1; and (c) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable. The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 by the Financial Officer for the financial period ended 30 June 2022. Signed in accordance with a resolution of the Directors. Winton Willesee Non-Executive Director Dated at Perth, Western Australia 25 August 2022 Level 32 Exchange Tower, 2 The Esplanade Perth WA 6000
GPO Box R1253 Perth WA 6844
RSM Australia Partners
T +61 (0) 8 9261 9100
F +61 (0) 8 9261 9111
www.rsm.com.au
INDEPENDENT AUDITOR’S REPORT
TO THE MEMBERS OF
NANOLLOSE LIMITED
Opinion
We have audited the financial report of Nanollose Limited (the Company), which comprises the statement of
financial position as at 30 June 2022, the statement of profit or loss and other comprehensive income, the
statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial
statements, including a summary of significant accounting policies, and the directors' declaration.
In our opinion, the accompanying financial report of the Company is in accordance with the Corporations Act 2001,
including:
(i)
Giving a true and fair view of the Company's financial position as at 30 June 2022 and of its financial
performance for the year then ended; and
(ii)
Complying with Australian Accounting Standards and the Corporations Regulations 2001.
Basis for Opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those
standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of
our report. We are independent of the Company in accordance with the auditor independence requirements of
the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards
Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the
financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to
the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's
report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our
opinion.
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
RSM Australia Partners is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the RSM network is an independent
accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
Key Audit Matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of
the financial report of the current period. These matters were addressed in the context of our audit of the financial
report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
Key Audit Matter
Share-based payments
Refer to Note 13 to the financial statements
How our audit addressed this matter
During the year, the Company issued options to
directors, an employee and the lead manager for
capital raising.
Our audit procedures included:
Reviewing the terms and conditions of the options
issued;
We determined this to be a key audit matter due to the
significant judgements involved in assessing the fair
value of the options issued during the year.
Obtaining the valuation models prepared by
management and assessing whether the models
were appropriate for valuing the options granted
during the year;
the
Challenging
key
assumptions used by management to value the
options;
Recalculating
reasonableness
the value of
of
to be recognised
the share-based
the
loss and other
in
payment expense
statement of profit or
comprehensive income; and
Assessing the adequacy of the disclosures in the
financial statements to ensure compliance with
Accounting Standards.
Other Information
The directors are responsible for the other information. The other information comprises the information included
in the Company's annual report for the year ended 30 June 2022 but does not include the financial report and the
auditor's report thereon.
Our opinion on the financial report does not cover the other information and accordingly we do not express any
form of assurance conclusion thereon.
In connection with our audit of the financial report, our responsibility is to read the other information and, in doing
so, consider whether the other information is materially inconsistent with the financial report or our knowledge
obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of the Directors for the Financial Report
The directors of the Company are responsible for the preparation of the financial report that gives a true and fair
view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal
control as the directors determine is necessary to enable the preparation of the financial report that gives a true
and fair view and is free from material misstatement, whether due to fraud or error.
In preparing the financial report, the directors are responsible for assessing the ability of the Company to continue
as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis
of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no
realistic alternative but to do so.
Auditor's Responsibilities for the Audit of the Financial Report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from
material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance
with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements
can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably
be expected to influence the economic decisions of users taken on the basis of this financial report.
A further description of our responsibilities for the audit of the financial report is located at the Auditing and
Assurance Standards Board website at: https://www.auasb.gov.au/auditors_responsibilities/ar2.pdf. This
description forms part of our auditor's report.
Report on the Remuneration Report
Opinion on the Remuneration Report
We have audited the Remuneration Report included in the directors’ report for the year ended 30 June 2022.
In our opinion, the Remuneration Report of Nanollose Limited, for the year ended 30 June 2022, complies with
section 300A of the Corporations Act 2001.
Responsibilities
The directors of the Company are responsible for the preparation and presentation of the Remuneration Report
in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the
Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.
RSM AUSTRALIA PARTNERS
Perth, WA
Dated: 25 August 2022
Alasdair Whyte
Partner
ASX ADDITIONAL INFORMATION
The shareholder information set out below was applicable as at 1 August 2022.
1. Quotation
Listed securities in Nanollose Limited are quoted on the Australian Securities Exchange under ASX code NC6
(Fully Paid Ordinary Shares) and NC6OA (Listed Options), and are not quoted on any other exchange.
2. Voting Rights
The voting rights attached to the Fully Paid Ordinary Shares (“Shares”) of the Company are:
(a)
at a meeting of members or classes of members each member entitled to vote may vote in person or
by proxy or by attorney; and
(b)
every member present in person, or by proxy or attorney:
(i)
on a show of hands, has one vote; and
(ii) on a poll, has one vote for each Share held.
There are no voting rights attached to any Options on issue.
3. Distribution of Shareholders
i)
Fully Paid Ordinary Shares
Shares Range
Holders
1 – 1,000
1,001 – 5,000
5,001 – 10,000
10,001 – 100,000
100,001 and above
Total
32
193
268
753
198
1,444
Units
4,808
758,565
2,169,093
28,171,103
117,782,799
148,886,368
%
0.00%
0.51%
1.46%
18.92%
79.11%
100.00%
On 1 August 2022, there were 320 holders of unmarketable parcels of less than 7,247 Shares (based
on the closing Share price of $0.069).
ii)
Listed Options exercisable at $0.15 on or before 5 July 2024
Shares Range
Holders
1 – 1,000
1,001 – 5,000
5,001 – 10,000
10,001 – 100,000
100,001 and above
Total
1
5
3
71
23
103
Units
5
21,421
28,809
3,480,152
18,738,248
22,268,635
%
-
0.10%
0.13%
15.63%
84.15%
100.00%
NANOLLOSE LIMITED ANNUAL REPORT 2022
PAGE 56
iii)
Class E Options exercisable at $0.10 on or before 31 May 2023
Shares Range
Holders
Units
1 – 1,000
1,001 – 5,000
5,001 – 10,000
10,001 – 100,000
100,001 and above
Total
-
-
-
-
1
1
1 Held by Anthony John Locantro
-
-
-
-
800,0001
800,000
iv)
Class G Options exercisable at $0.08 on or before 31 October 2023
Shares Range
Holders
Units
1 – 1,000
1,001 – 5,000
5,001 – 10,000
10,001 – 100,000
100,001 and above
Total
1Held by Heidi Beatty
-
-
-
-
1
1
-
-
-
-
500,0001
500,000
v)
Class H Options exercisable at $0.10 on or before 20 April 2024
Shares Range
Holders
Units
1 – 1,000
1,001 – 5,000
5,001 – 10,000
10,001 – 100,000
100,001 and above
Total
-
-
-
-
1
1
1Held by Cheena Corporate Pty Ltd
Continue reading text version or see original annual report in PDF format above